Answers are grounded in this paper and cite their sources.
Event size re-estimation (ESR) is a natural extension of sample size re-estimation (SSR) to clinical trials with a time-to-event endpoint. Even though the same Type I error approaches are shared between ESR and SSR, the survival endpoint is more complicated than continuous and binary ones. We look into all the popular methods to control Type I error rate under ESR. Moreover, we propose the specification of incorporating stratification factors into the combination test for clinical trials with data from different stages. The properties of all the above methods are thoroughly studied and discussed.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: